What is Survodutide?
Research Focus: Metabolic
Survodutide (BI 456906) is a dual agonist targeting both the GLP-1 receptor and the glucagon receptor. This dual action is being investigated for its potential to treat obesity and metabolic dysfunction-associated steatohepatitis (MASH/NASH).
At a Glance
Survodutide is a synthetic peptide that combines the appetite-suppressing and glucose-lowering effects of GLP-1 agonism with the metabolic benefits of glucagon receptor agonism, such as increased energy expenditure and lipolysis. This section provides a general overview of its research context.
About Survodutide
Survodutide is a synthetic peptide that combines the appetite-suppressing and glucose-lowering effects of GLP-1 agonism with the metabolic benefits of glucagon receptor agonism, such as increased energy expenditure and lipolysis.
How It Works
GLP-1 Action
Reduces appetite, slows gastric emptying, and improves glucose control.
Glucagon Action
Glucagon signaling, when balanced with GLP-1, can increase energy expenditure and promote the breakdown of fat (lipolysis), particularly in the liver.
Current Research Insights
Liver Fat Reduction
Survodutide has shown promising results in reducing liver fat content in MASH/NASH patients, suggesting a powerful effect beyond simple weight loss.
Areas of Study
MASH/NASH
Primary focus on treating metabolic dysfunction-associated steatohepatitis (fatty liver disease).
Chronic Weight Management
Investigated for significant weight loss in individuals with obesity.
Survodutide is strictly intended for laboratory and clinical research:
- Available exclusively from authorized research suppliers
- Not FDA-approved for general therapeutic use
- Comprehensive safety, efficacy, and dosage guidelines remain under ongoing investigation
FAQs
Research
- Phase 2 and 3 clinical trials evaluating Survodutide in MASH/NASH and obesity.
- Research on dual GLP-1/Glucagon receptor agonism and its effects on hepatic steatosis.
(The above references are representative and support the research context of this peptide, GLP hormone or regenerative therapy. All claims are for research purposes only and do not imply approved medical use.)